Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review

Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review

The application of immune checkpoint inhibitors has proven to be an effective treatment for cancer. Immune checkpoints such as programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin-3 (TIM-3)...

Full description

Bibliographic Details
Main Authors:	Yu-Quan Li, Xue-Mei Chen, Gui-Fei Si, Xue-Min Yuan
Format:	Article
Language:	English
Published:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2024-04-01
Series:	Biomolecules & Biomedicine
Subjects:	Immunotherapy programmed cell death protein 1 (PD-1) programmed cell death protein 1 ligand 1 (PD-L1) lymphocyte activation gene-3 (LAG-3) combination therapy
Online Access:	https://bjbms.org/ojs/index.php/bjbms/article/view/10339

Similar Items

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
by: Margarita Udall, et al.
Published: (2018-02-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

PROTECTION OF T-LYMPHOCYTES VIA PD-1 RECEPTOR: NEW MOLECULAR MECHANISM OF CANCER IMMUNOTHERAPY
by: Sandor Szabo
Published: (2019-12-01)

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
by: Maria A.V. Marzolini, et al.
Published: (2015-03-01)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
by: Lucas V. dos Santos, et al.
Published: (2021-03-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

Understanding and overcoming resistance to immunotherapy in genitourinary cancers
by: Sean T Evans, et al.
Published: (2024-12-01)

Clinical and Prognostic Significance of Tumor-Infiltrating CD8+ T Cells and PD-L1 Expression in Primary Gastrointestinal Stromal Tumors
by: Xiangfei Sun, et al.
Published: (2021-12-01)

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
by: Zhenqing Wang, et al.
Published: (2021-08-01)

PD-1 and PD-L1 Expression in Indian Women with Breast Cancer
by: Kishan R. Bharadwa, et al.
Published: (2022-01-01)

Assays for predicting and monitoring responses to lung cancer immunotherapy
by: Cristina Teixidó, et al.
Published: (2015-06-01)

Advances in cancer immunotherapy 2019 – latest trends
by: Stephan Kruger, et al.
Published: (2019-06-01)

Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives
by: Gerardo Cazzato, et al.
Published: (2023-06-01)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
by: Mohammadsaleh Jahangir, et al.
Published: (2022-12-01)

Immune-Checkpoint Blockade Therapy in Lymphoma
by: Ayumi Kuzume, et al.
Published: (2020-07-01)

FR -Inmunoterapia en el carcinoma de células de Merkel
by: M.F. García-Gil, et al.
Published: (2021-06-01)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
by: Niki Karachaliou, et al.
Published: (2015-06-01)

Anti-Bovine Programmed Death-1 Rat–Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle
by: Tomohiro Okagawa, et al.
Published: (2017-06-01)

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
by: Yiming Wei, et al.
Published: (2022-04-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
by: Suxia Geng, et al.
Published: (2022-08-01)

Advances in immunotherapy for treatment of lung cancer
by: Jean G. Bustamante Alvarez, et al.
Published: (2015-09-01)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
by: Yuedi Zhang, et al.
Published: (2022-06-01)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
by: Ismael Rodriguez, et al.
Published: (2023-09-01)

Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma
by: Jie Shen, et al.
Published: (2022-10-01)

Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review
by: Nicoletta Mancianti, et al.
Published: (2024-03-01)

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
by: Lu Yu, et al.
Published: (2022-09-01)

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
by: Magdalena Bojko, et al.
Published: (2024-04-01)

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
by: Sandra Schöniger, et al.
Published: (2022-10-01)

The Anticancer Power of the Immune System – New Perspectives for Patients with Triple-Negative Breast Cancer
by: Katarzyna Rygiel
Published: (2019-11-01)

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
by: Jennifer Kleponis, et al.
Published: (2015-09-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
by: Said Dermime, et al.
Published: (2021-10-01)

The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01)

The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases
by: Dominika Katarzyna Madras, et al.
Published: (2020-04-01)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
by: Debasree Banerjee, et al.
Published: (2018-06-01)

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
by: Che-Wei Wang, et al.
Published: (2024-02-01)

Breast Cancer Immunotherapy: From Biology to Current Clinical Applications
by: Jorge Henrique Santos Leal, et al.
Published: (2020-06-01)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
by: Feng Xian, et al.
Published: (2023-04-01)

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
by: Maarten Versteven, et al.
Published: (2018-03-01)